Biomarker Development for Immuno-Oncology and Cancer immunotherapy: Simultaneous Digital Counting of Nucleic-Acids and Proteins at 800-Plex
Both the ENCODE and TCGA projects highlighted the value of quantifying multiple biomarker classes (DNA, RNA, and protein) from cancer tumor samples. In the case of cancer immunotherapy, the importance of measuring non-DNA markers (e.g., mRNA and proteins) becomes crucial since cell signaling, tumor microenvironment, and protein-protein interactions dominate over pure SNP-based (DNA) driver mutations in determining therapeutic response. Combining multiple data types together into a single correlated analysis, however, is adversely effected by the drastically different methodologies utilized for measurement. For example, the fluorescence signal intensity obtained from a camera imaging a protein array (e.g., RPPA) is very difficult to correlate directly with an RNA sequencing count of a clonally amplified, cDNA-converted, mRNA molecule. New developments in multiple biomarker-class optical barcode counting significantly reduce this problem. Recent developments using NanoString Technology has shown how optical barcode technology can be utilized for multiplexed digital counting of proteins and be combined with simultaneous digital counting of nucleic acids on a single platform.
Date: 8 June 2015, 12:00 (Monday, 7th week, Trinity 2015)
Venue: Wellcome Trust Centre for Human Genetics, Headington OX3 7BN
Venue Details: Room A and B
Speaker: Dr Joseph Beechem (Nanostring Technologies Inc)
Organising department: Wellcome Trust Centre for Human Genetics
Organisers: Marta Guderska (University of Oxford), Susan Wilson (University of Oxford, Wellcome Trust Centre for Human Genetics)
Organiser contact email address:
Part of: Oxford Genomic Centre Seminars
Booking required?: Recommended
Audience: Public
Editors: Anne Bowtell, Claire Escher Kessler, Marta Guderska